Health
Sputnik-V Covid-19 vaccine trial shows 'encouraging' results
Sputnik-V Covid-19 vaccine trial shows 'encouraging' results
Credit: SputnikVaccine.com

The "Sputnik-V" Covid-19 vaccine produced a neutralising antibody response in all 76 participants, according to data published Friday in the medical journal The Lancet. The vaccine often caused mild side effects such as fever.

Experts have claimed the sample size of the Russian study was small and urged for more research on the elderly.

The Brazilian institute Tecpar announced plans to conduct the phase III trials on 10,000 volunteers at the start of next year.

Regional News • Americas • Brazil
Brazilian state in talks with Russia to produce Covid-19 vaccine
Brazilian state in talks with Russia to produce Covid-19 vaccine
Credit: Tecpar (Public Domain)

Brazil’s Parana state announced the intention to locally produce the Sputnik V Covid-19 vaccine. The Parana Technology Institute (Tecpar) would be responsible for tests and later the production of the Russian vaccine.

An agreement should be signed by the governor of Paraná, Ratinho Júnior, and by the Russian ambassador, Sergey Akopov, this Wednesday.

Tecpar’s spokesman João Pedro Schonarth stated earlier Tuesday, "This signature of the Government of Paraná and Russia is important for the exchange to be made possible. Each step at its proper time. We cannot skip steps. We cannot make leaps when dealing with an extremely serious matter"

The announcement took Brazil’s regulators and health experts by surprise, with some raising doubts about the institute’s capacity to produce large volumes of a new vaccine from scratch.